QPS Tapped for Two New FIH Studies
Two companies have just selected QPS Netherlands to conduct their First-in-Human studies. Acticor Biotech, a Paris-based biotechnology company focused on the treatment of acute ischemic stroke, selected the QPS facility in Groningen, The Netherlands, to manage a Phase I clinical study. The goal of the study is to assess safety and tolerance as well as […]
QPS Tapped for Two New FIH Studies Read More »
